MARKET

BPMC

BPMC

Blueprint
NASDAQ

Real-time Quotes | Nasdaq Last Sale

103.81
-2.55
-2.40%
After Hours: 103.81 0 0.00% 16:00 09/28 EDT
OPEN
105.03
PREV CLOSE
106.36
HIGH
106.28
LOW
102.18
VOLUME
501.64K
TURNOVER
--
52 WEEK HIGH
125.61
52 WEEK LOW
79.08
MARKET CAP
6.08B
P/E (TTM)
17.13
1D
5D
1M
3M
1Y
5Y
Insider Sell: Blueprint Medicines
MT Newswires · 1d ago
Blueprint Medicines Corp (BPMC) EVP and Chief Legal Officer Tracey L Mccain Sold $2. ...
GuruFocus News · 1d ago
Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion
Zacks.com · 09/20 15:59
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on , the Compensation Committee of Blueprint Medicin...
PR Newswire - PRF · 09/03 20:01
Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines' Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines' President, Research & Development, will participate virtually in a fireside chat ...
PR Newswire · 09/02 12:00
Invesco V.I. Global Fund Buys Lonza Group, Intuitive Surgical Inc, Ambu A/S, Sells Nuance ...
GuruFocus News · 09/01 21:38
Is Blueprint Medicines Corporation's (NASDAQ:BPMC) Latest Stock Performance A Reflection Of Its Financial Health?
Blueprint Medicines (NASDAQ:BPMC) has had a great run on the share market with its stock up by a significant 12% over...
Simply Wall St. · 08/25 10:34
Blueprint Medicines Corp (BPMC) CEO and President Jeffrey W. Albers Sold $2.3 million of Shares
GuruFocus News · 08/23 11:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BPMC. Analyze the recent business situations of Blueprint through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

42.86%Strong Buy
28.57%Buy
28.57%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BPMC stock price target is 119.00 with a high estimate of 152.00 and a low estimate of 81.00.
High152.00
Average119.00
Low81.00
Current 103.81
EPS
Actual
Estimate
1.294.467.6210.79
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 387
Institutional Holdings: 63.00M
% Owned: 107.56%
Shares Outstanding: 58.57M
TypeInstitutionsShares
Increased
110
4.55M
New
53
1.20M
Decreased
69
2.15M
Sold Out
35
3.57M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.68%
Pharmaceuticals & Medical Research
-1.98%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jeffrey Albers
Chief Financial Officer
Michael Landsittel
Corporate Executive
Fouad Namouni
Chief Operating Officer
Kathryn Haviland
Chief Human Resource Officer
Debra Durso-Bumpus
Executive Vice President
Anthony Boral
Senior Vice President
Christopher Murray
Chief Scientific Officer
Percy Carter
Chief Compliance Officer
Tracey McCain
Vice President/Controller
Ariel Hurley
Other
Becker Hewes
Other
Christina Rossi
Lead Director/Independent Director
Lynn Seely
Independent Director
Alexis Borisy
Independent Director
Lonnel Coats
Independent Director
George Demetri
Independent Director
Mark Goldberg
Independent Director
Nicholas Lydon
Independent Director
Charles Rowland
No Data
About BPMC
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Webull offers kinds of Blueprint Medicines Corp stock information, including NASDAQ:BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.